Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/26/2024 | $14.00 | Buy | B. Riley Securities |
5/26/2023 | $11.00 | Buy | Citigroup |
3/24/2022 | $13.00 | Market Outperform | CJS Securities |
11/29/2021 | $14.00 | Buy | Goldman Sachs |
10/25/2021 | $14.00 | Buy | Citigroup |
Revenues for the third quarter increased 8.2% to $206.8 million, compared to $191.2 million in the same period in 2023. Net loss was $14.0 million in the third quarter, compared to a net loss of $12.9 million in the same period last year. Adjusted EBITDA was $45.7 million, a 17.8% increase from $38.8 million in the same period last year. Loss from operations margin was 0.8% in the third quarter, compared to 5.8% in the same period in 2023. Adjusted EBITDA margin was 22.1% in the third quarter, compared to 20.3% in the same period last year. GAAP net loss per share for the third quarter was $0.07, compared to $0.06 in the third quarter of 2023. Adjusted earnings per share for the q
Mirion (NYSE:MIR) announced today that it will release financial results for third quarter 2024 after market close on Tuesday, October 29, 2024. Following the news release, the company will host a conference call the next day, Wednesday, October 30, 2024, at 11:00 am ET to discuss the results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at https://ir.mirion.com/news-events. A telephonic replay will be available shortly after the conclusion of the call and until November 13, 2024. Participants may access the replay at 1-844-512-2921 or 1-412-317-6671 w
Revenues for the second quarter increased 5.0% to $207.1 million, compared to $197.2 million in the same period in 2023. Net loss was $12.0 million in the second quarter, compared to a net loss of $28.4 million in the same period last year. Adjusted EBITDA was $48.8 million, a 10.2% increase from $44.3 million in the same period last year. Income (loss) from operations margin was 1.1% in the second quarter, compared to (5.4)% in the same period in 2023. Adjusted EBITDA margin was 23.6% in the second quarter, compared to 22.5% in the same period last year. GAAP net loss per share for the second quarter was $0.06, compared to $0.14 in the second quarter of 2023. Adjusted earnings pe
SC 13D/A - Mirion Technologies, Inc. (0001809987) (Subject)
SC 13G/A - Mirion Technologies, Inc. (0001809987) (Subject)
SC 13D/A - Mirion Technologies, Inc. (0001809987) (Subject)
Revenues for the third quarter increased 8.2% to $206.8 million, compared to $191.2 million in the same period in 2023. Net loss was $14.0 million in the third quarter, compared to a net loss of $12.9 million in the same period last year. Adjusted EBITDA was $45.7 million, a 17.8% increase from $38.8 million in the same period last year. Loss from operations margin was 0.8% in the third quarter, compared to 5.8% in the same period in 2023. Adjusted EBITDA margin was 22.1% in the third quarter, compared to 20.3% in the same period last year. GAAP net loss per share for the third quarter was $0.07, compared to $0.06 in the third quarter of 2023. Adjusted earnings per share for the q
Mirion Technologies (NYSE:MIR), a leading provider of advanced radiation safety solutions, today announced that it has been awarded two significant contracts to support the Sizewell C project, a new 3.2-gigawatt power station for Britain. Leveraging EDF expertise and EPR (European Pressurised Reactor) technology, Sizewell C will generate low-carbon electricity sufficient to power approximately 6 million homes. The development, based in East Suffolk, will mirror the design of the Hinkley Point C nuclear power station currently under construction in the Somerset region. As a key supplier to nuclear power plants globally, Mirion Technologies has demonstrated its capability and commitment to d
Mirion (NYSE:MIR), a leading provider of radiation safety solutions supporting advancements in nuclear power and cancer care, today announced that it will host an Investor Day on Tuesday, December 3, 2024, beginning at 2:00 p.m. ET. The event will be held at the New York Stock Exchange and webcast live. Due to limited capacity, in-person attendance is by invitation only. Institutional investors and financial analysts wishing to attend in-person should contact [email protected] before in-person registration closes on Monday, November 18, 2024. Interested parties can register for the live webcast at https://mirion-investor-day.open-exchange.net/. A link to the live webcast will also be available
Mirion Technologies (NYSE:MIR) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $192.600 million which beat the analyst consensus estimate of $191.355 million by 0.65 percent. This is a 5.77 percent increase over sales of $182.100 million the same period last year.
SunCHECK® Platform Enhancements, New MRgRT QA Solutions, and More MELBOURNE, Fla., Sept. 29, 2023 /PRNewswire/ -- Sun Nuclear, a Mirion Medical company (NYSE:MIR), will showcase enhancements and additions to its comprehensive Quality Management portfolio at the ASTRO Annual Meeting, October 1-3, in San Diego, California. The Sun Nuclear booth (#1835) will highlight new features and insights for the SunCHECK® Platform, new MR capabilities for proven SRS/SBRT QA solutions, and the new SIM+™ Pro laser system for patient alignment. Complete Quality Management in One PlatformAvail
Brings over 15 years of accounting and M&A auditing experience to further enhance Janus's financial reporting and integration capabilities Janus International Group, Inc. (NYSE:JBI) ("Janus" or the "Company"), a leading provider of cutting-edge access control technologies and building product solutions for the self-storage and other commercial and industrial sectors, today announced the appointment of David Vanevenhoven as Chief Accounting Officer, on February 20, 2023. He will report directly to Janus's CFO, Anselm Wong. Mr. Vanevenhoven brings over 15 years of experience in financial accounting and auditing to oversee Janus's accounting function, financial reporting, and internal control
Mirion Technologies, Inc. ("Mirion," "we" or the "Company") (NYSE:MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion's CEO, Tom Logan, who had been acting as President of the business segment. Michael joins Mirion from Novartis, where he most recently served as the Head of Radioligand Imaging for the Advanced Accelerator Applications business. Prior to Novartis, Michael spent five years at Jubilant Pharma where he served in several different roles with increasing le
10-Q - Mirion Technologies, Inc. (0001809987) (Filer)
8-K - Mirion Technologies, Inc. (0001809987) (Filer)
144 - Mirion Technologies, Inc. (0001809987) (Subject)
4 - Mirion Technologies, Inc. (0001809987) (Issuer)
4 - Mirion Technologies, Inc. (0001809987) (Issuer)
4 - Mirion Technologies, Inc. (0001809987) (Issuer)
B. Riley Securities initiated coverage of Mirion Technologies with a rating of Buy and set a new price target of $14.00
Citigroup resumed coverage of Mirion Technologies with a rating of Buy and set a new price target of $11.00
CJS Securities initiated coverage of Mirion Technologies with a rating of Market Outperform and set a new price target of $13.00